Drug resistance associated with antiangiogenesis therapy.
about
Targeting Angiogenesis in Biliary Tract Cancers: An Open OptionModulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Angiogenesis inhibitors: current strategies and future prospects.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerPien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1 α /VEGF-A Pathway in Colorectal Cancer.Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factorCisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.Efficacy of traditional Chinese medicine in treating cancer.Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinomaCS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches.Mechanisms of resistance to vascular endothelial growth factor blockade.Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy.Tumor vasculature: the Achilles' heel of cancer?Tumour endothelial cells acquire drug resistance in a tumour microenvironment.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?Angiopoietins Modulate Survival, Migration, and the Components of the Ang-Tie2 Pathway of Chronic Lymphocytic Leukaemia (CLL) Cells In Vitro.Metastatic gastric cancer - focus on targeted therapies.Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.Stromal cells in breast cancer as a potential therapeutic target.Endogenous Matrix-Derived Inhibitors of Angiogenesis.
P2860
Q30398807-16B0690C-DF17-4890-9C32-0E1E460FDA31Q33733303-97157AE9-4109-40DE-94F9-6AF1B46418AAQ33824587-BD6A5A95-39F1-4211-974D-B34FBA5FC2F4Q34056376-DE386432-0045-4F7E-BA06-850C33229F53Q34128953-65862A53-F1FC-483E-8662-95F3522AACB5Q35026527-4D105A2D-9BDA-4B79-AB5F-6FE92FFD15FBQ35091440-019EEC5E-EE68-4BE5-84A8-45348A6E2654Q36089989-60C76B4E-93D9-42CA-81BF-CEEFA6E1691CQ36502153-A56CEB65-B23D-4559-AA74-F049896EEEC8Q36725301-AF24999A-62FF-4269-B2D3-743BE1162A14Q37640001-D16AF2D5-5638-43B3-88AB-57D5D360230AQ37735637-31FB6C48-E987-407B-895E-BCAD31379083Q37857056-86AAB94D-D7B3-45D7-BF28-F95FB05F1698Q37956587-37A0CB82-FAA8-414F-B2AB-FFD56CD6386DQ38002923-A849227E-9F58-4683-B7AC-2DC078F8F98EQ38057420-05261E98-740C-4A7F-8796-889ACD27BC43Q38072018-BCA1570D-272B-40E2-82F4-8339FE257640Q38757723-E247CB71-EA46-4D61-AC5D-9085DE55FE19Q38763633-B82B14EA-31C4-4CDF-AA13-83E3521BCD7EQ40535831-7AF3AD71-3A63-436C-B22D-58470B4A5340Q41907024-1CD6A840-A7CE-40C3-88E5-5E77E7B2EDD0Q53699332-6B74674D-CA6F-4780-A604-9569EF75D4FCQ55016792-50CC0E13-6C28-4FFA-84D1-49E27ADFF6FBQ55506580-08D1B58E-8A20-48A3-9B4F-41DE9275E925
P2860
Drug resistance associated with antiangiogenesis therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug resistance associated with antiangiogenesis therapy.
@en
Drug resistance associated with antiangiogenesis therapy.
@nl
type
label
Drug resistance associated with antiangiogenesis therapy.
@en
Drug resistance associated with antiangiogenesis therapy.
@nl
prefLabel
Drug resistance associated with antiangiogenesis therapy.
@en
Drug resistance associated with antiangiogenesis therapy.
@nl
P2860
P1476
Drug resistance associated with antiangiogenesis therapy.
@en
P2093
Hans Petter Eikesdal
P2860
P304
P356
10.1016/J.SEMCANCER.2009.05.006
P577
2009-06-11T00:00:00Z